AbbVie is battling on multiple fronts against specialized drug classes like IL inhibitors, JAK inhibitors, and BTK inhibitors, as well as direct product competitors to Botox. This multi-faceted competition requires sophisticated market intelligence and commercial execution to protect market share in its core therapeutic areas.
Filing excerpt
AbbVie's immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars and other competitive products intended to treat a number of disease states, and AbbVie's oncology products compete with targeted therapies including BTK inhibitors, ADCs, cell therapies and other competitive products intended to treat certain cancers.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10kmarketShareLossGet every 10-K signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/1ee293ec-32ec-49e6-b958-131e880d180e returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "1ee293ec-32ec-49e6-b958-131e880d180e",
"signal_type": "sec-10k",
"signal_subtype": "marketShareLoss",
"detected_at": "2026-02-24T09:18:27.385+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie is battling on multiple fronts against specialized drug classes like IL inhibitors, JAK inhibitors, and BTK inhibitors, as well as direct product competitors to Botox. This multi-faceted competition requires sophisticated market intelligence and commercial execution to protect market share in its core therapeutic areas.",
"summary": "Facing intense competition across immunology, oncology, and aesthetics portfolios from specialized therapies.",
"excerpts": "AbbVie's immunology products compete with IL-23 inhibitors, IL-17 inhibitors, JAK inhibitors, biosimilars and other competitive products intended to treat a number of disease states, and AbbVie's oncology products compete with targeted therapies including BTK inhibitors, ADCs, cell therapies and other competitive products intended to treat certain cancers.",
"relevance": 0.7,
"sentiment": "negative",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm",
"filing_date": "2026-02-20",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Urgency to improve",
"signal_category": "market",
"technologies_mentioned": [
"IL-23 inhibitors",
"IL-17 inhibitors",
"JAK inhibitors",
"BTK inhibitors",
"ADCs",
"cell therapies"
]
}
}
curl https://signals.autobound.ai/v1/signals/1ee293ec-32ec-49e6-b958-131e880d180e \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.